Io Biotech, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
IOBT
Io Biotech, INCSCHEDULE: Jorey Chernett Exits IO Biotech Position
Jorey Chernett has filed an exit statement confirming the disposal of all beneficial ownership in IO Biotech, Inc.
IOBT
Io Biotech, INCHBM Healthcare Investments (Cayman) Ltd. filed an amendment disclosing a reduction in its beneficial ownership of IO Biotech, Inc. common stock to 3.3%.
IOBT
Io Biotech, INCJorey Chernett has reported a beneficial ownership of 6.31% of IO Biotech, Inc.'s common stock, holding 4,543,532 shares.
IOBT
Io Biotech, INCPoint72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly reported a 5.6% beneficial ownership stake in IO Biotech, Inc.
IOBT
Io Biotech, INCVivo Capital entities have filed an amended Schedule 13G, reporting their beneficial ownership in IO Biotech, Inc. has fallen below the 5% threshold.
IOBT
Io Biotech, INCJorey Chernett has reported a beneficial ownership of 5.3% of IO Biotech, Inc.'s common stock, totaling 3,477,162 shares.
IOBT
Io Biotech, INCSamsara BioCapital, L.P., along with its general partner and managing member, filed an amended Schedule 13G indicating a 3.8% passive ownership stake in IO Biotech, Inc. as of December 31, 2024.
IOBT
Io Biotech, INCHBM Healthcare Investments (Cayman) Ltd. has filed an amended Schedule 13G, correcting its beneficial ownership in IO Biotech, Inc. to include 1,578,947 shares from warrants, bringing its total stake to 8.2% as of December 31, 2023.